723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models

723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models

Bibliographic Details
Main Authors:	Christopher Nirschl, Kristin Morris, Heather Brodkin, Nesreen Ismail, Andres Salmeron, Philipp Steiner, Zoe Steuert, Jenna Sullivan, William Winston, Cindy Seidel-Dugan, Ethika Tyagi, Josue Canales, Dan Hicklin
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

1059 Spatial analysis of tumor infiltrating lymphocyte populations in syngeneic mouse tumor models after treatment with IL-12 (mWTX-330) and IL-2 (WTX-124) INDUKINETM molecules
by: Christopher J Nirschl, et al.
Published: (2023-11-01)

718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models
by: Christopher Nirschl, et al.
Published: (2021-11-01)

1058 Optimal antitumor immunity triggered by WTX-124, a clinical stage conditionally activated INDUKINETM molecule that releases fully potent IL-2 in the tumor microenvironment
by: Christopher J Nirschl, et al.
Published: (2023-11-01)

252 The combination of ACT and INDUKINE therapy leads to improved antitumor immunity in solid tumors
by: Kyriakos Economides, et al.
Published: (2023-11-01)

1075 Development of WTX-712, a conditionally active IL-21 INDUKINETM molecule for the treatment of cancer
by: Kyriakos Economides, et al.
Published: (2023-11-01)

1074 PK/RO modeling of WTX-124, a tumor-activated IL-2 prodrug, highlights the potential for a substantially improved therapeutic index compared to other IL-2 molecules
by: Christopher J Nirschl, et al.
Published: (2023-11-01)

TUMOR BINDING-PROPERTIES OF B72.3 FV FRAGMENTS
by: Owens, R, et al.
Published: (1991)

737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors
by: Brendan Curti, et al.
Published: (2023-11-01)

Anti-tumor effect of aquaporin 3 monoclonal antibody on syngeneic mouse tumor model
by: Manami Tanaka, et al.
Published: (2022-10-01)

Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model
by: Raziye Piranlioglu, et al.
Published: (2019-03-01)

Tumor-localized catalases can fail to alter tumor growth and transcriptional profiles in subcutaneous syngeneic mouse tumor models
by: Allison Sheen, et al.
Published: (2023-08-01)

Characterization of immune cell populations in syngeneic murine tumor models
by: Sofie Snipstad, et al.
Published: (2023-05-01)

Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model
by: Fábio T. Watanabe, et al.
Published: (2011-01-01)

WTX beyond WNT signaling pathway
by: Zhang Qingling, et al.
Published: (2023-01-01)

Dual-Armed Oncolytic Myxoma Virus Encoding IFN-γ and CD47 Promotes Lymphocyte Infiltration and Tumor Suppression of Syngeneic Murine Melanoma
by: Jong Kyu Woo, et al.
Published: (2023-09-01)

Comparison of cisplatin-induced anti-tumor response in CT26 syngeneic tumors of three BALB/c substrains
by: Jeong Eun Gong, et al.
Published: (2021-12-01)

Mutational spectrum of <it>WTX</it>, <it>WT1</it>, <it>CTNNB1</it>, <it>APC</it> and <it>PLCG2</it> genes in Wilms tumor defined by massive parallel resequencing
by: Barros Bruna D, et al.
Published: (2012-10-01)

Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments.
by: Jong W Yu, et al.
Published: (2018-01-01)

DNA based neoepitope vaccination induces tumor control in syngeneic mouse models
by: Nadia Viborg, et al.
Published: (2023-05-01)

Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model
by: Sanjana Ghosh, et al.
Published: (2022-09-01)

Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
by: Wenyan Zhong, et al.
Published: (2020-01-01)

Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models
by: Wade R. Gutierrez, et al.
Published: (2021-01-01)

Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types
by: Jasneet Kaur Khalsa, et al.
Published: (2020-08-01)

Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity
by: Matthew R. Schuelke, et al.
Published: (2019-03-01)

Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma.
by: Yuki Egawa, et al.
Published: (2018-01-01)

A benzimidazole derivative as an effective antitumor agent in terms of syngeneic lung tumors and melanoma treatment
by: E. F. Komarova, et al.
Published: (2022-03-01)

The impact of tumor immunogenicity on cancer pain phenotype using syngeneic oral cancer mouse models
by: Nicole L. Horan, et al.
Published: (2022-09-01)

Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model.
by: Kai-Ti Lin, et al.
Published: (2017-01-01)

1056 XTX301, a tumor activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models
by: Wilson Guzman, et al.
Published: (2023-11-01)

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models
by: Yanxia Li, et al.
Published: (2022-01-01)

SITE-613
by: Poag, C, et al.
Published: (1987)

Tumor Colonization and Therapy by <i>Escherichia coli</i> Nissle 1917 Strain in Syngeneic Tumor-Bearing Mice Is Strongly Affected by the Gut Microbiome
by: Ivaylo Gentschev, et al.
Published: (2022-12-01)

The <it>WTX/AMER1 </it>gene family: evolution, signature and function
by: Boutet Agnès, et al.
Published: (2010-09-01)

MiR-613 suppresses retinoblastoma cell proliferation, invasion, and tumor formation by targeting E2F5
by: Yiting Zhang, et al.
Published: (2017-03-01)

1400 YF550-C1 promotes T cell activation, cytokines release and induces robust tumor growth inhibition in syngeneic and PDX tumor models
by: Na An, et al.
Published: (2023-11-01)

Dynamic differentiation of F4/80+ tumor-associated macrophage and its role in tumor vascularization in a syngeneic mouse model of colorectal liver metastasis
by: Ting Qiao, et al.
Published: (2023-02-01)

Searching for Promoters to Drive Stable and Long-Term Transgene Expression in Fibroblasts for Syngeneic Mouse Tumor Models
by: Dina V. Antonova, et al.
Published: (2020-08-01)

Infiltration of Immune Competent Cells into Primary Tumors and Their Surrounding Connective Tissues in Xenograft and Syngeneic Mouse Models
by: Marlon Metzen, et al.
Published: (2021-04-01)

Intra-Tumoral Nerve-Tracing in a Novel Syngeneic Model of High-Grade Serous Ovarian Carcinoma
by: Jeffrey L. Barr, et al.
Published: (2021-12-01)

5-Aminolevulinic Acid Triggered by Ultrasound Halts Tumor Proliferation in a Syngeneic Model of Breast Cancer
by: Federica Foglietta, et al.
Published: (2021-09-01)